2021 World Conference on Lung Cancer (Posters)-FP09. Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy

FP09. Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy

Back to course

Video Transcription

Video Summary

The video discusses a study on MOBA-CERT, an EGFR tyrosine kinase inhibitor, for platinum pretreated patients with EGFR exon 20 insertion positive non-small cell lung cancer. The study aimed to assess the efficacy and safety of MOBA-CERT in patients with and without prior anti-PD-L1 therapy. The study included 114 patients and the overall response rate was 28% in all platinum pretreated patients. The duration of response was 17.5 months in the subgroup with prior anti-PD-L1 therapy and 11 months in the subgroup without prior therapy. Progression-free survival and overall survival were similar in both subgroups. The safety profile of MOBA-CERT was manageable in both populations.

Asset Subtitle

Pasi A. Janne

Meta Tag

Speaker Pasi A. Janne

Topic Novel Therapeutics and Targeted Therapies

Keywords

MOBA-CERT

EGFR tyrosine kinase inhibitor

platinum pretreated patients

EGFR exon 20 insertion positive non-small cell lung cancer

anti-PD-L1 therapy